Biocon’s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon’s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.
Global Markets | European shares fall again as Mideast war drags on
European shares extended their decline on Tuesday, mirroring a global equity selloff as investors grappled with the prospect of a prolonged Middle East conflict. A